Endocrinology, diabetes & metabolism

Effectiveness and Safety of Tirzepatide Compared to Dulaglutide in Type 2 Diabetes With or Without Heart and Blood Vessel Disease

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

This network meta-analysis evaluates different doses of tirzepatide compared to dulaglutide for glycemic control, weight loss, and safety in type 2 diabetes mellitus.

  • Tirzepatide may provide varying levels of glycemic control depending on the dose used.
  • Different doses of tirzepatide are associated with distinct outcomes in weight loss compared to dulaglutide.
  • Safety profiles for tirzepatide at various doses are compared with those of dulaglutide.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Apr '25
Effectiveness and Safety of Dulaglutide Biosimilar LY05008 Compared to Original Dulaglutide (Trulicity) in Chinese Adults with Type 2 Diabetes
top 20% journal
cited by 2 papers
randomized controlled trial
Apr '25
Comparing Increasing Dulaglutide Dose to Switching to Tirzepatide in People with Type 2 Diabetes Not Controlled by Low Dulaglutide
top 2% journal
cited by 10 papers
randomized controlled trial
Aug '26
Effectiveness and safety of different once-weekly diabetes drugs that mimic gut hormones
top 10% journal
systematic review
Mar '26
Safety and effectiveness of switching from dulaglutide to tirzepatide in people with type 2 diabetes across different starting conditions
top 10% journal
randomized controlled trial
Apr '25
Effectiveness and side effects of approved incretin-based diabetes drugs compared to placebo
top 5% journal
cited by 16 papers
systematic review
Aug '17
Once-weekly dulaglutide’s effects on blood sugar levels in patients by gender, diabetes duration, and starting HbA1c
cited by 82 papers
randomized controlled trial
Mar '26
Comparing new incretin treatments for heart and kidney protection in type 2 diabetes
cited by 1 paper
journal article
Oct '18
Safety and effectiveness of LY3298176, a new drug targeting two hormone receptors, in people with type 2 diabetes: a controlled phase 2 trial
top 1% journal
cited by 753 papers
randomized controlled trial

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief